{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T02:02:57Z","timestamp":1791424977362,"version":"4.3.3"},"reference-count":66,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T00:00:00Z","timestamp":1773705600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T00:00:00Z","timestamp":1778025600000},"content-version":"vor","delay-in-days":50,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100000289","name":"Cancer Research UK","doi-asserted-by":"publisher","award":["RCCCEA-Nov21\\100001"],"award-info":[{"award-number":["RCCCEA-Nov21\\100001"]}],"id":[{"id":"10.13039\/501100000289","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000265","name":"RCUK | Medical Research Council","doi-asserted-by":"publisher","award":["MC-A564-5QC70"],"award-info":[{"award-number":["MC-A564-5QC70"]}],"id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000265","name":"RCUK | Medical Research Council","doi-asserted-by":"publisher","award":["MR\/W019132\/1"],"award-info":[{"award-number":["MR\/W019132\/1"]}],"id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Victoria\u2019s Secret Global Fund for Women\u2019s Cancers Career Development Award, in partnership with Pelotonia and AACR"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>For all drugs, effective target engagement requires sufficient intracellular concentrations of drug to be reached, but whether tumour heterogeneity impacts drug distribution and efficacy is poorly studied. Poly (ADP-ribose) polymerase (PARP) inhibitors have transformed treatment opportunities for women with high-grade serous ovarian carcinoma, but resistance remains a clinical hurdle in this highly heterogeneous tumour type. Here, we present a patient-derived explant multi-modal imaging pipeline, which demonstrates that cell-intrinsic PARP inhibitor accumulation is highly variable, both between patients and within tumours. Spatial transcriptomics reveals enrichment of apoptotic and lysosomal signatures in high-drug regions. Rucaparib, an intrinsically fluorescent PARP inhibitor, accumulates heterogeneously at the single-cell level, with rucaparib-high cells demonstrating increased drug response relative to rucaparib-low. Mechanistically, lysosomal sequestration creates a rucaparib reservoir that determines drug levels in the nucleus. Perturbation of lysosomal content alters intracellular levels of weak base PARP inhibitors rucaparib and niraparib, but not olaparib. Together these data suggest that lysosomes act as a reservoir for a subset of PARP inhibitor drugs to improve drug response.<\/jats:p>","DOI":"10.1038\/s41467-026-70558-1","type":"journal-article","created":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T14:45:51Z","timestamp":1773758751000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Multimodal imaging reveals a lysosomal drug reservoir that drives heterogeneous distribution of PARP inhibitors"],"prefix":"10.1038","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-5427-7336","authenticated-orcid":false,"given":"Carmen","family":"R. Moncayo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8434-4465","authenticated-orcid":false,"given":"Restuadi","family":"Restuadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guanying","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8641-193X","authenticated-orcid":false,"given":"Daniel","family":"Marks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paula","family":"Ortega-Prieto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-7881-9573","authenticated-orcid":false,"given":"Emily","family":"Doherty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-0440-5894","authenticated-orcid":false,"given":"Nathalie","family":"Lambie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chad","family":"Whilding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivan","family":"Andrew","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6501-883X","authenticated-orcid":false,"given":"Alex","family":"Montoya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bhavik","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-0339-514X","authenticated-orcid":false,"given":"Katie","family":"Tyson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5721-6994","authenticated-orcid":false,"given":"Betheney R.","family":"Pennycook","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren","family":"Pendergast","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincen","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0795-3467","authenticated-orcid":false,"given":"Zoltan","family":"Takats","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0602-1131","authenticated-orcid":false,"given":"Nik","family":"Matthews","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1203-588X","authenticated-orcid":false,"given":"George R.","family":"Young","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2852-0767","authenticated-orcid":false,"given":"Priyanka","family":"Verma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3092-0724","authenticated-orcid":false,"given":"Pavel","family":"Shliaha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurence","family":"Game","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1114-1509","authenticated-orcid":false,"given":"Boris","family":"Lenhard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9387-7586","authenticated-orcid":false,"given":"Iain","family":"McNeish","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina","family":"Fotopoulou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6684-8114","authenticated-orcid":false,"given":"Alexis R.","family":"Barr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3699-4911","authenticated-orcid":false,"given":"Paula","family":"Cunnea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1434-8329","authenticated-orcid":false,"given":"Zoe","family":"Hall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0317-2540","authenticated-orcid":false,"given":"Louise","family":"Fets","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,17]]},"reference":[{"key":"70558_CR1","doi-asserted-by":"publisher","first-page":"1 18","DOI":"10.1038\/s41589-018-0136-y","volume":"14","author":"L Fets","year":"2018","unstructured":"Fets, L. et al. MCT2 mediates concentration-dependent inhibition of glutamine metabolism by MOG. Nat. Chem. Biol. 14, 1 18 (2018).","journal-title":"Nat. Chem. Biol."},{"key":"70558_CR2","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1038\/nrclinonc.2017.166","volume":"15","author":"I Dagogo-Jack","year":"2017","unstructured":"Dagogo-Jack, I. & Shaw, A. T. Tumour heterogeneity and resistance to cancer therapies. Nat. Rev. Clin. Oncol. 15, 81 (2017).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"70558_CR3","doi-asserted-by":"publisher","first-page":"101055","DOI":"10.1016\/j.xcrm.2023.101055","volume":"4","author":"P Cunnea","year":"2023","unstructured":"Cunnea, P. et al. Spatial and temporal intra-tumoral heterogeneity in advanced HGSOC: Implications for surgical and clinical outcomes. Cell Rep. Med. 4, 101055 (2023).","journal-title":"Cell Rep. Med."},{"key":"70558_CR4","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-47271-y","volume":"15","author":"E Denisenko","year":"2024","unstructured":"Denisenko, E. et al. Spatial transcriptomics reveals discrete tumour microenvironments and autocrine loops within ovarian cancer subclones. Nat. Commun. 15, 2860 (2024).","journal-title":"Nat. Commun."},{"key":"70558_CR5","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1002\/path.2696","volume":"221","author":"AA Ahmed","year":"2010","unstructured":"Ahmed, A. A. et al. Driver mutations in TP53 are ubiquitous in high grade serous carcinoma of the ovary. J. Pathol. 221, 49\u201356 (2010).","journal-title":"J. Pathol."},{"key":"70558_CR6","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1038\/nrc4019","volume":"15","author":"DD Bowtell","year":"2015","unstructured":"Bowtell, D. D. et al. Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer. Nat. Rev. Cancer 15, 668\u2013679 (2015).","journal-title":"Nat. Rev. Cancer"},{"key":"70558_CR7","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1038\/nrc2946","volume":"10","author":"DDL Bowtell","year":"2010","unstructured":"Bowtell, D. D. L. The genesis and evolution of high-grade serous ovarian cancer. Nat. Rev. Cancer 10, 803\u2013808 (2010).","journal-title":"Nat. Rev. Cancer"},{"key":"70558_CR8","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1038\/nature14410","volume":"521","author":"A-M Patch","year":"2015","unstructured":"Patch, A.-M. et al. Whole-genome characterization of chemoresistant ovarian cancer. Nature 521, 489\u2013494 (2015).","journal-title":"Nature"},{"key":"70558_CR9","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1016\/j.ccell.2020.01.003","volume":"37","author":"Z Hu","year":"2020","unstructured":"Hu, Z. et al. The repertoire of serous ovarian cancer non-genetic heterogeneity revealed by single-cell sequencing of normal fallopian tube epithelial cells. Cancer Cell 37, 226\u2013242.e7 (2020).","journal-title":"Cancer Cell"},{"key":"70558_CR10","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-23171-3","volume":"12","author":"A Nath","year":"2021","unstructured":"Nath, A. et al. Evolution of core archetypal phenotypes in progressive high grade serous ovarian cancer. Nat. Commun. 12, 3039 (2021).","journal-title":"Nat. Commun."},{"key":"70558_CR11","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1038\/s41586-022-05496-1","volume":"612","author":"I V\u00e1zquez-Garc\u00eda","year":"2022","unstructured":"V\u00e1zquez-Garc\u00eda, I. et al. Ovarian cancer mutational processes drive site-specific immune evasion. Nature 612, 778\u2013786 (2022).","journal-title":"Nature"},{"key":"70558_CR12","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1038\/nature10166","volume":"474","author":"D Bell","year":"2011","unstructured":"Bell, D. et al. Integrated genomic analyses of ovarian carcinoma. Nature 474, 609\u2013615 (2011).","journal-title":"Nature"},{"key":"70558_CR13","doi-asserted-by":"publisher","first-page":"2495","DOI":"10.1056\/NEJMoa1810858","volume":"379","author":"K Moore","year":"2018","unstructured":"Moore, K. et al. Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer. N. Engl. J. Med. 379, 2495\u20132505 (2018).","journal-title":"N. Engl. J. Med."},{"key":"70558_CR14","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1200\/JCO.22.01549","volume":"41","author":"P DiSilvestro","year":"2023","unstructured":"DiSilvestro, P. et al. Overall survival with maintenance olaparib at a 7-year follow-up in patients with newly diagnosed advanced ovarian cancer and a BRCA mutation: The SOLO1\/GOG 3004 trial. J. Clin. Oncol. 41, 609\u2013617 (2023).","journal-title":"J. Clin. Oncol."},{"key":"70558_CR15","doi-asserted-by":"publisher","first-page":"220118","DOI":"10.1098\/rsob.220118","volume":"12","author":"AJ Wicks","year":"2022","unstructured":"Wicks, A. J., Krastev, D. B., Pettitt, S. J., Tutt, A. N. J. & Lord, C. J. Opinion: PARP inhibitors in cancer\u2014what do we still need to know? Open Biol. 12, 220118 (2022).","journal-title":"Open Biol."},{"key":"70558_CR16","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms2506","volume":"4","author":"GM Thurber","year":"2013","unstructured":"Thurber, G. M. et al. Single-cell and subcellular pharmacokinetic imaging allows insight into drug action in vivo. Nat. Commun. 4, 1504 (2013).","journal-title":"Nat. Commun."},{"key":"70558_CR17","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/j.cmet.2018.09.009","volume":"29","author":"BC King","year":"2019","unstructured":"King, B. C. et al. Complement component C3 is highly expressed in human pancreatic islets and prevents \u03b2 cell death via ATG16L1 interaction and autophagy regulation. Cell Metab. 29, 202\u2013210.e6 (2019).","journal-title":"Cell Metab."},{"key":"70558_CR18","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1165\/rcmb.2017-0405OC","volume":"60","author":"HS Kulkarni","year":"2019","unstructured":"Kulkarni, H. S. et al. Intracellular C3 protects human airway epithelial cells from stress-associated cell death. Am. J. Respir. Cell Mol. Biol. 60, 144\u2013157 (2019).","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"key":"70558_CR19","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1038\/nature23643","volume":"549","author":"ML Burr","year":"2017","unstructured":"Burr, M. L. et al. CMTM6 maintains the expression of PD-L1 and regulates anti-tumour immunity. Nature 549, 101\u2013105 (2017).","journal-title":"Nature"},{"key":"70558_CR20","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1038\/nature23669","volume":"549","author":"R Mezzadra","year":"2017","unstructured":"Mezzadra, R. et al. Identification of CMTM6 and CMTM4 as PD-L1 protein regulators. Nature 549, 106\u2013110 (2017).","journal-title":"Nature"},{"key":"70558_CR21","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-05031-9","volume":"9","author":"J Michelena","year":"2018","unstructured":"Michelena, J. et al. Analysis of PARP inhibitor toxicity by multidimensional fluorescence microscopy reveals mechanisms of sensitivity and resistance. Nat. Commun. 9, 2678 (2018).","journal-title":"Nat. Commun."},{"key":"70558_CR22","doi-asserted-by":"publisher","first-page":"1316","DOI":"10.2967\/jnumed.117.205765","volume":"59","author":"S Kossatz","year":"2018","unstructured":"Kossatz, S. et al. Direct imaging of drug distribution and target engagement of the PARP inhibitor rucaparib. J. Nucl. Med. 59, 1316\u20131320 (2018).","journal-title":"J. Nucl. Med."},{"key":"70558_CR23","doi-asserted-by":"publisher","DOI":"10.1083\/jcb.202102001","volume":"220","author":"C Yang","year":"2021","unstructured":"Yang, C. & Wang, X. Lysosome biogenesis: regulation and functions. J. Cell Biol. 220, e202102001 (2021).","journal-title":"J. Cell Biol."},{"key":"70558_CR24","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1186\/s13046-017-0592-3","volume":"36","author":"B Englinger","year":"2017","unstructured":"Englinger, B. et al. Intrinsic fluorescence of the clinically approved multikinase inhibitor nintedanib reveals lysosomal sequestration as resistance mechanism in FGFR-driven lung cancer. J. Exp. Clin. Cancer Res. 36, 122 (2017).","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"70558_CR25","doi-asserted-by":"publisher","first-page":"3157","DOI":"10.3390\/ijms21093157","volume":"21","author":"M Krchniakova","year":"2020","unstructured":"Krchniakova, M., Skoda, J., Neradil, J., Chlapek, P. & Veselska, R. Repurposing tyrosine kinase inhibitors to overcome multidrug resistance in cancer: a focus on transporters and lysosomal sequestration. Int. J. Mol. Sci. 21, 3157 (2020).","journal-title":"Int. J. Mol. Sci."},{"key":"70558_CR26","doi-asserted-by":"publisher","first-page":"3886","DOI":"10.1038\/s41388-019-0695-8","volume":"38","author":"S Llanos","year":"2019","unstructured":"Llanos, S. et al. Lysosomal trapping of palbociclib and its functional implications. Oncogene 38, 3886\u20133902 (2019).","journal-title":"Oncogene"},{"key":"70558_CR27","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1038\/s41589-019-0308-4","volume":"15","author":"CY-S Chung","year":"2019","unstructured":"Chung, C. Y.-S. et al. Covalent targeting of the vacuolar H+-ATPase activates autophagy via mTORC1 inhibition. Nat. Chem. Biol. 15, 776\u2013785 (2019).","journal-title":"Nat. Chem. Biol."},{"key":"70558_CR28","doi-asserted-by":"publisher","first-page":"200200","DOI":"10.1098\/rsob.200200","volume":"10","author":"EW Trotter","year":"2020","unstructured":"Trotter, E. W. & Hagan, I. M. Release from cell cycle arrest with Cdk4\/6 inhibitors generates highly synchronized cell cycle progression in human cell culture. Open Biol. 10, 200200 (2020).","journal-title":"Open Biol."},{"key":"70558_CR29","doi-asserted-by":"publisher","first-page":"jcs247940","DOI":"10.1242\/jcs.247940","volume":"133","author":"SJ Scott","year":"2020","unstructured":"Scott, S. J., Suvarna, K. S. & D\u2019Avino, P. P. Synchronization of human retinal pigment epithelial-1 cells in mitosis. J. Cell Sci. 133, jcs247940 (2020).","journal-title":"J. Cell Sci."},{"key":"70558_CR30","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1124\/dmd.112.050054","volume":"41","author":"F Kazmi","year":"2013","unstructured":"Kazmi, F. et al. Lysosomal sequestration (Trapping) of lipophilic amine (cationic amphiphilic) drugs in immortalized human hepatocytes (Fa2N-4 Cells). Drug Metab. Dispos. 41, 897\u2013905 (2013).","journal-title":"Drug Metab. Dispos."},{"key":"70558_CR31","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1124\/mol.114.097451","volume":"88","author":"H Burger","year":"2015","unstructured":"Burger, H. et al. Lysosomal sequestration determines intracellular imatinib levels. Mol. Pharmacol. 88, 477\u2013487 (2015).","journal-title":"Mol. Pharmacol."},{"key":"70558_CR32","doi-asserted-by":"publisher","first-page":"113328","DOI":"10.1016\/j.biopha.2022.113328","volume":"153","author":"P Mlejnek","year":"2022","unstructured":"Mlejnek, P., Havlasek, J., Pastvova, N., Dolezel, P. & Dostalova, K. Lysosomal sequestration of weak base drugs, lysosomal biogenesis, and cell cycle alteration. Biomed. Pharmacother. 153, 113328 (2022).","journal-title":"Biomed. Pharmacother."},{"key":"70558_CR33","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.18632\/oncotarget.2732","volume":"6","author":"B Zhitomirsky","year":"2014","unstructured":"Zhitomirsky, B. & Assaraf, Y. G. Lysosomal sequestration of hydrophobic weak base chemotherapeutics triggers lysosomal biogenesis and lysosome-dependent cancer multidrug resistance. Oncotarget 6, 1143\u20131156 (2014).","journal-title":"Oncotarget"},{"key":"70558_CR34","doi-asserted-by":"publisher","first-page":"7337","DOI":"10.1158\/1078-0432.CCR-11-1667","volume":"17","author":"KJ Gotink","year":"2011","unstructured":"Gotink, K. J. et al. Lysosomal sequestration of sunitinib: a novel mechanism of drug resistance. Clin. Cancer Res. 17, 7337\u20137346 (2011).","journal-title":"Clin. Cancer Res."},{"key":"70558_CR35","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.drup.2015.11.004","volume":"24","author":"B Zhitomirsky","year":"2016","unstructured":"Zhitomirsky, B. & Assaraf, Y. G. Lysosomes as mediators of drug resistance in cancer. Drug Resist. Updat. 24, 23\u201333 (2016).","journal-title":"Drug Resist. Updat."},{"key":"70558_CR36","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1126\/science.aat9689","volume":"364","author":"DJ Greenwood","year":"2019","unstructured":"Greenwood, D. J. et al. Subcellular antibiotic visualization reveals a dynamic drug reservoir in infected macrophages. Science 364, 1279\u20131282 (2019).","journal-title":"Science"},{"key":"70558_CR37","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1038\/s41580-023-00676-x","volume":"25","author":"C Settembre","year":"2024","unstructured":"Settembre, C. & Perera, R. M. Lysosomes as coordinators of cellular catabolism, metabolic signalling and organ physiology. Nat. Rev. Mol. Cell Biol. 25, 223\u2013245 (2024).","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"70558_CR38","doi-asserted-by":"publisher","DOI":"10.1126\/science.abj5559","volume":"380","author":"N Malik","year":"2023","unstructured":"Malik, N. et al. Induction of lysosomal and mitochondrial biogenesis by AMPK phosphorylation of FNIP1. Science 380, eabj5559 (2023).","journal-title":"Science"},{"key":"70558_CR39","doi-asserted-by":"publisher","unstructured":"Beernaert, B. et al. Chromosomal instability shapes the tumor microenvironment of esophageal adenocarcinoma via a cGAS\u2013chemokine\u2013myeloid axis. bioRxiv 2025.05.06.652454 https:\/\/doi.org\/10.1101\/2025.05.06.652454 (2025).","DOI":"10.1101\/2025.05.06.652454"},{"key":"70558_CR40","doi-asserted-by":"publisher","unstructured":"Lv, B. et al. A TBK1-independent primordial function of STING in lysosomal biogenesis. Mol. Cell https:\/\/doi.org\/10.1016\/j.molcel.2024.08.026 (2024).","DOI":"10.1016\/j.molcel.2024.08.026"},{"key":"70558_CR41","doi-asserted-by":"publisher","first-page":"1078","DOI":"10.1038\/s41586-025-09240-3","volume":"644","author":"A McPherson","year":"2025","unstructured":"McPherson, A. et al. Ongoing genome doubling shapes evolvability and immunity in ovarian cancer. Nature 644, 1078\u20131087 (2025).","journal-title":"Nature"},{"key":"70558_CR42","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/j.jconrel.2015.09.044","volume":"217","author":"K Yokoi","year":"2015","unstructured":"Yokoi, K. et al. Liposomal doxorubicin extravasation controlled by phenotype-specific transport properties of tumor microenvironment and vascular barrier. J. Control. Release 217, 293\u2013299 (2015).","journal-title":"J. Control. Release"},{"key":"70558_CR43","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1038\/nrc1893","volume":"6","author":"AI Minchinton","year":"2006","unstructured":"Minchinton, A. I. & Tannock, I. F. Drug penetration in solid tumours. Nat. Rev. Cancer 6, 583\u2013592 (2006).","journal-title":"Nat. Rev. Cancer"},{"key":"70558_CR44","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1002\/cpdd.575","volume":"8","author":"GI Shapiro","year":"2019","unstructured":"Shapiro, G. I. et al. Pharmacokinetic study of rucaparib in patients with advanced solid tumors. Clin. Pharmacol. Drug Dev. 8, 107\u2013118 (2019).","journal-title":"Clin. Pharmacol. Drug Dev."},{"key":"70558_CR45","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1093\/jjco\/hyab013","volume":"51","author":"K Yonemori","year":"2021","unstructured":"Yonemori, K. et al. The safety, tolerability and pharmacokinetics of niraparib in Japanese patients with solid tumours: results of a phase I dose-escalation study. Jpn. J. Clin. Oncol. 51, 693\u2013699 (2021).","journal-title":"Jpn. J. Clin. Oncol."},{"key":"70558_CR46","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1055\/s-2003-41864","volume":"125","author":"J Sehouli","year":"2003","unstructured":"Sehouli, J. et al. IMO? - intraoperatives mapping des Ovarialkarzinoms. Zentralblatt F. R. Gyn Kologie 125, 129\u2013135 (2003).","journal-title":"Zentralblatt F. R. Gyn Kologie"},{"key":"70558_CR47","doi-asserted-by":"publisher","first-page":"1202","DOI":"10.1016\/j.ejso.2010.09.008","volume":"36","author":"C Fotopoulou","year":"2010","unstructured":"Fotopoulou, C. et al. Can complete tumor resection be predicted in advanced primary epithelial ovarian cancer? A systematic evaluation of 360 consecutive patients. Eur. J. Surg. Oncol. (EJSO) 36, 1202\u20131210 (2010).","journal-title":"Eur. J. Surg. Oncol. (EJSO)"},{"key":"70558_CR48","doi-asserted-by":"publisher","first-page":"1354","DOI":"10.1097\/IGC.0000000000000767","volume":"26","author":"D Querleu","year":"2016","unstructured":"Querleu, D. et al. European Society of Gynaecologic Oncology quality indicators for advanced ovarian cancer surgery. Int. J. Gynecol. Cancer 26, 1354\u20131363 (2016).","journal-title":"Int. J. Gynecol. Cancer"},{"key":"70558_CR49","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1136\/ijgc-2020-001248","volume":"30","author":"C Fotopoulou","year":"2020","unstructured":"Fotopoulou, C. et al. Quality indicators for advanced ovarian cancer surgery from the European Society of Gynaecological Oncology (ESGO): 2020 update. Int. J. Gynecol. Cancer 30, 436 (2020).","journal-title":"Int. J. Gynecol. Cancer"},{"key":"70558_CR50","doi-asserted-by":"publisher","first-page":"11080","DOI":"10.1021\/acs.analchem.0c00826","volume":"92","author":"A Dannhorn","year":"2020","unstructured":"Dannhorn, A. et al. Universal sample preparation unlocking multimodal molecular tissue imaging. Anal. Chem. 92, 11080\u201311088 (2020).","journal-title":"Anal. Chem."},{"key":"70558_CR51","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1038\/nmeth.2019","volume":"9","author":"J Schindelin","year":"2012","unstructured":"Schindelin, J. et al. Fiji: an open-source platform for biological-image analysis. Nat. Methods 9, 676\u2013682 (2012).","journal-title":"Nat. Methods"},{"key":"70558_CR52","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-17204-5","volume":"7","author":"P Bankhead","year":"2017","unstructured":"Bankhead, P. et al. QuPath: open source software for digital pathology image analysis. Sci. Rep. 7, 16878 (2017).","journal-title":"Sci. Rep."},{"key":"70558_CR53","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.7150\/ijbs.41395","volume":"16","author":"L Morosi","year":"2020","unstructured":"Morosi, L. et al. Quantitative determination of niraparib and olaparib tumor distribution by mass spectrometry imaging. Int J. Biol. Sci. 16, 1363\u20131375 (2020).","journal-title":"Int J. Biol. Sci."},{"key":"70558_CR54","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1007\/s13361-013-0607-z","volume":"24","author":"G Robichaud","year":"2013","unstructured":"Robichaud, G., Garrard, K. P., Barry, J. A. & Muddiman, D. C. MSiReader: an open-source interface to view and analyze high resolving power ms imaging files on matlab platform. J. Am. Soc. Mass Spectrom. 24, 718\u2013721 (2013).","journal-title":"J. Am. Soc. Mass Spectrom."},{"key":"70558_CR55","doi-asserted-by":"publisher","first-page":"15545","DOI":"10.1073\/pnas.0506580102","volume":"102","author":"A Subramanian","year":"2005","unstructured":"Subramanian, A. et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl. Acad. Sci. USA 102, 15545\u201315550 (2005).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"70558_CR56","doi-asserted-by":"publisher","first-page":"D672","DOI":"10.1093\/nar\/gkad1025","volume":"52","author":"M Milacic","year":"2023","unstructured":"Milacic, M. et al. The Reactome Pathway Knowledgebase 2024. Nucleic Acids Res. 52, D672\u2013D678 (2023).","journal-title":"Nucleic Acids Res."},{"key":"70558_CR57","doi-asserted-by":"crossref","unstructured":"Marks, D. et al. Assessing PARP trapping dynamics in ovarian cancer using a CRISPR-engineered FRET biosensor. Cell. Rep. Methods. 6, 101270 (2026).","DOI":"10.1016\/j.crmeth.2025.101270"},{"key":"70558_CR58","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1186\/s12859-021-04344-9","volume":"22","author":"DR Stirling","year":"2021","unstructured":"Stirling, D. R. et al. CellProfiler 4: improvements in speed, utility and usability. BMC Bioinform 22, 433 (2021).","journal-title":"BMC Bioinform"},{"key":"70558_CR59","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1038\/s41592-020-01018-x","volume":"18","author":"C Stringer","year":"2021","unstructured":"Stringer, C., Wang, T., Michaelos, M. & Pachitariu, M. Cellpose: a generalist algorithm for cellular segmentation. Nat. Methods 18, 100\u2013106 (2021).","journal-title":"Nat. Methods"},{"key":"70558_CR60","doi-asserted-by":"publisher","first-page":"10350","DOI":"10.1021\/acs.analchem.8b02172","volume":"90","author":"S Shen","year":"2018","unstructured":"Shen, S. et al. Surfactant cocktail-aided extraction\/precipitation\/on-pellet digestion strategy enables efficient and reproducible sample preparation for large-scale quantitative proteomics. Anal. Chem. 90, 10350\u201310359 (2018).","journal-title":"Anal. Chem."},{"key":"70558_CR61","doi-asserted-by":"publisher","first-page":"1400","DOI":"10.1074\/mcp.M114.044305","volume":"14","author":"R Bruderer","year":"2015","unstructured":"Bruderer, R. et al. Extending the limits of quantitative proteome profiling with data-independent acquisition and application to acetaminophen-treated three-dimensional liver microtissues* [S]. Mol. Cell. Proteom. 14, 1400\u20131410 (2015).","journal-title":"Mol. Cell. Proteom."},{"key":"70558_CR62","doi-asserted-by":"publisher","first-page":"2104","DOI":"10.1021\/acs.jproteome.2c00145","volume":"21","author":"AM Frankenfield","year":"2022","unstructured":"Frankenfield, A. M., Ni, J., Ahmed, M. & Hao, L. Protein contaminants matter: building universal protein contaminant libraries for DDA and DIA proteomics. J. Proteome Res. 21, 2104\u20132113 (2022).","journal-title":"J. Proteome Res."},{"key":"70558_CR63","doi-asserted-by":"publisher","first-page":"2513","DOI":"10.1074\/mcp.M113.031591","volume":"13","author":"J Cox","year":"2014","unstructured":"Cox, J. et al. Accurate proteome-wide label-free quantification by delayed normalization and maximal peptide ratio extraction, termed MaxLFQ*. Mol. Cell. Proteom. 13, 2513\u20132526 (2014).","journal-title":"Mol. Cell. Proteom."},{"key":"70558_CR64","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1038\/nmeth.3901","volume":"13","author":"S Tyanova","year":"2016","unstructured":"Tyanova, S. et al. The Perseus computational platform for comprehensive analysis of (prote)omics data. Nat. Methods 13, 731\u2013740 (2016).","journal-title":"Nat. Methods"},{"key":"70558_CR65","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1089\/omi.2011.0118","volume":"16","author":"G Yu","year":"2012","unstructured":"Yu, G., Wang, L.-G., Han, Y. & He, Q.-Y. clusterProfiler: an R package for comparing biological themes among gene clusters. OMICS: A J. Integr. Biol. 16, 284\u2013287 (2012).","journal-title":"OMICS: A J. Integr. Biol."},{"key":"70558_CR66","doi-asserted-by":"publisher","first-page":"1447","DOI":"10.1021\/acs.jproteome.9b00640","volume":"19","author":"KJ Adams","year":"2020","unstructured":"Adams, K. J. et al. Skyline for small molecules: a unifying software package for quantitative metabolomics. J. Proteome Res. 19, 1447\u20131458 (2020).","journal-title":"J. Proteome Res."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-70558-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-70558-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-70558-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T07:03:29Z","timestamp":1778051009000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-70558-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,17]]},"references-count":66,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["70558"],"URL":"https:\/\/doi.org\/10.1038\/s41467-026-70558-1","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,17]]},"assertion":[{"value":"31 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The Authors declare the following competing interests: I.M. has undertaken advisory boards for AstraZeneca, Clovis Oncology\/pharma& and GSK. Imperial College has received institutional grant support from AstraZeneca. All other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"4086"}}